BRPI0817524A2 - liberação prolongada de análogos de compstatina provenientes de géis - Google Patents

liberação prolongada de análogos de compstatina provenientes de géis

Info

Publication number
BRPI0817524A2
BRPI0817524A2 BRPI0817524A BRPI0817524A BRPI0817524A2 BR PI0817524 A2 BRPI0817524 A2 BR PI0817524A2 BR PI0817524 A BRPI0817524 A BR PI0817524A BR PI0817524 A BRPI0817524 A BR PI0817524A BR PI0817524 A2 BRPI0817524 A2 BR PI0817524A2
Authority
BR
Brazil
Prior art keywords
gels
prolonged release
compstatin analogues
compstatin
analogues
Prior art date
Application number
BRPI0817524A
Other languages
English (en)
Portuguese (pt)
Inventor
François Cedric
Deschatelets Pascal
Olson Paul
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of BRPI0817524A2 publication Critical patent/BRPI0817524A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0817524A 2007-10-02 2008-10-02 liberação prolongada de análogos de compstatina provenientes de géis BRPI0817524A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US2646008P 2008-02-05 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (1)

Publication Number Publication Date
BRPI0817524A2 true BRPI0817524A2 (pt) 2017-05-02

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817524A BRPI0817524A2 (pt) 2007-10-02 2008-10-02 liberação prolongada de análogos de compstatina provenientes de géis

Country Status (12)

Country Link
US (1) US20110182877A1 (https=)
EP (1) EP2207530A4 (https=)
JP (1) JP2010540654A (https=)
KR (2) KR20150080007A (https=)
CN (1) CN101854916A (https=)
AU (1) AU2008308657A1 (https=)
BR (1) BRPI0817524A2 (https=)
CA (1) CA2701470A1 (https=)
MX (1) MX2010003630A (https=)
RU (1) RU2505311C2 (https=)
WO (1) WO2009046198A2 (https=)
ZA (1) ZA201002365B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP5829685B2 (ja) 2010-09-03 2015-12-09 サンテン・エス・エー・エス 眼の疾患を処置するための油中水型エマルション
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
PT2425814E (pt) 2010-09-03 2013-09-02 Novagali Pharma Sa Emulsão de tipo água em óleo para tratamento de uma doença ocular
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
EP3524258B1 (en) * 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) * 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN102977191B (zh) * 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system

Also Published As

Publication number Publication date
CN101854916A (zh) 2010-10-06
JP2010540654A (ja) 2010-12-24
RU2505311C2 (ru) 2014-01-27
KR20150080007A (ko) 2015-07-08
CA2701470A1 (en) 2009-04-09
EP2207530A2 (en) 2010-07-21
KR20100094453A (ko) 2010-08-26
US20110182877A1 (en) 2011-07-28
RU2010113513A (ru) 2011-11-10
AU2008308657A1 (en) 2009-04-09
EP2207530A4 (en) 2013-09-11
ZA201002365B (en) 2010-12-29
WO2009046198A3 (en) 2009-07-16
MX2010003630A (es) 2010-04-21
WO2009046198A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
BRPI0817524A2 (pt) liberação prolongada de análogos de compstatina provenientes de géis
BRPI0911269A2 (pt) análogos de halicondrina b
EP2398483A4 (en) Oxyntomodulin Analogs
DK2361256T3 (da) Cyclohexenyl-nukleinsyreanaloger
EP2096917A4 (en) Cyclopamine ANALOG
DE602009000580D1 (de) Endoskopsystem
BRPI0922508A2 (pt) Análogos de nucleosídeo
EP2029597A4 (en) purine analogs
PT2260053E (pt) Análogos de oxitocina
EP1994182A4 (en) Slide-off nucleobase Analogs
EP2298608A4 (en) ELECTRICAL BEAM
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0718548A2 (pt) Estabilização de vacinas por liofilização
EP2246950A4 (en) EYELET
FI20085277A0 (fi) Kohdunsisäinen järjestelmä
EP2312590A4 (en) Wire harness
EP2327960A4 (en) MICROELECTROMECHANICAL SYSTEM
DE602006009894D1 (de) Verbesserter Flash-ADC
EP2110789A4 (en) PAPER MONEY PROCESSOR
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
DK2237727T3 (da) Vævsretraktor
EP2321966A4 (en) BRIGHTNESS EVALUATION
CR10675A (es) Analogos de 2-fenoxipirimidinona
BRPI0811864A2 (pt) Derivados de ácido cistéico de peptídeos antivirais
BRPI0811132A2 (pt) Preparação de catalisadores de paládio-ouro

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]